A bill to amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
About This Bill
Committee
Latest Action · January 4, 2022
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.